Suppr超能文献

cERBB-2/Her-2 过表达与子宫癌肉瘤的预后意义。

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma.

机构信息

Department of Medical Oncology, Dokuz Eylül University Institute of Oncology, IZMIR, TURKEY.

出版信息

Turk Patoloji Derg. 2023;39(1):55-63. doi: 10.5146/tjpath.2022.01588.

Abstract

OBJECTIVE

There is not enough data in the literature regarding Her-2 overexpression in uterine carcinosarcomas or its association with the prognosis. The aim of this study was to determine the Her-2 overexpression rate in uterine carcinosarcoma and to evaluate its relationship with the prognosis.

MATERIAL AND METHOD

Her-2 protein and gene status were evaluated by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively, in hysterectomy specimens from 51 patients with uterine carcinosarcoma.

RESULTS

Her-2 protein expression in the epithelial component was negative in 42 patients (score 0 in 33 cases, score (+1) in 9 cases), score (+2) in 7 patients and score (+3) in 2 patients. None of the patients had Her-2 protein expression within the sarcomatous component of the tumors. Her-2 gene was not amplified in epithelial or mesenchymal tumor areas according to the FISH method. There was no difference between the Her-2 overexpression negative and positive groups in terms of disease-free survival (DFS) and overall survival (OS). Her-2 overexpression was significantly higher in tumors of patients diagnosed at 65 years or older (p=0.046).

CONCLUSION

In our study, no relationship could be shown between Her-2 overexpression and prognosis in uterine carcinosarcoma. More comprehensive studies are needed to illustrate the relationship between Her-2 overexpression and carcinosarcoma prognosis.

摘要

目的

关于子宫癌肉瘤中 Her-2 过表达及其与预后的关系,文献中数据不足。本研究旨在确定子宫癌肉瘤中 Her-2 过表达率,并评估其与预后的关系。

材料与方法

对 51 例子宫癌肉瘤患者的子宫切除术标本分别采用免疫组织化学(IHC)和荧光原位杂交(FISH)检测 Her-2 蛋白和基因状态。

结果

42 例患者的上皮成分中 Her-2 蛋白表达阴性(33 例评分为 0,9 例评分为(+1),7 例评分为(+2),2 例评分为(+3))。肿瘤的肉瘤成分中均未见 Her-2 蛋白表达。根据 FISH 方法,上皮或间叶肿瘤区域均未扩增 Her-2 基因。在无病生存(DFS)和总生存(OS)方面,Her-2 过表达阴性和阳性组之间无差异。在诊断年龄为 65 岁或以上的患者中,Her-2 过表达显著更高(p=0.046)。

结论

在本研究中,未显示 Her-2 过表达与子宫癌肉瘤的预后之间存在关系。需要更全面的研究来阐明 Her-2 过表达与癌肉瘤预后之间的关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a92/10518127/8d9ad615b198/TurkPatolojiDerg-39-12144-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验